• Bioinvent International AB, of Lund, Sweden, said it signed an extension to its 2009 license agreement with Mitsubishi Tanabe Pharma Corp., of Osaka, Japan, for the development of antibodies from Bioinvents' n-CoDeR library. Under the terms of the extension, Mitsubishi Tanabe will continue to have access to Bioinvent's discovery and development technology platform for a further two years and can develop up to eight antibody programs.